215 related articles for article (PubMed ID: 34662459)
1. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
Yanda MK; Cebotaru L
FASEB J; 2021 Nov; 35(11):e21987. PubMed ID: 34662459
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.
Yanda MK; Cha B; Cebotaru CV; Cebotaru L
J Biol Chem; 2019 Nov; 294(45):17090-17104. PubMed ID: 31570523
[TBL] [Abstract][Full Text] [Related]
3. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Yanda MK; Liu Q; Cebotaru L
J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
[TBL] [Abstract][Full Text] [Related]
4. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
5. Myofibroblast depletion reduces kidney cyst growth and fibrosis in autosomal dominant polycystic kidney disease.
Dwivedi N; Jamadar A; Mathew S; Fields TA; Rao R
Kidney Int; 2023 Jan; 103(1):144-155. PubMed ID: 36273656
[TBL] [Abstract][Full Text] [Related]
6. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
[TBL] [Abstract][Full Text] [Related]
7. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
[TBL] [Abstract][Full Text] [Related]
8. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
9. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
[TBL] [Abstract][Full Text] [Related]
10. Basolateral chloride transporters in autosomal dominant polycystic kidney disease.
Lebeau C; Hanaoka K; Moore-Hoon ML; Guggino WB; Beauwens R; Devuyst O
Pflugers Arch; 2002 Sep; 444(6):722-31. PubMed ID: 12355171
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].
Miranda N; Miranda F; Rinaldi L; Stratigis S; Capasso G
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832438
[TBL] [Abstract][Full Text] [Related]
12. Zebrafish Model as a Screen to Prevent Cyst Inflation in Autosomal Dominant Polycystic Kidney Disease.
Oliveira I; Jacinto R; Pestana S; Nolasco F; Calado J; Lopes SS; Roxo-Rosa M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445719
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease.
Yanda MK; Tomar V; Cebotaru L
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1517-1529. PubMed ID: 34329764
[TBL] [Abstract][Full Text] [Related]
14. Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.
Jansson K; Venugopal J; Sánchez G; Magenheimer BS; Reif GA; Wallace DP; Calvet JP; Blanco G
J Membr Biol; 2015 Dec; 248(6):1145-57. PubMed ID: 26289599
[TBL] [Abstract][Full Text] [Related]
15. CFTR and PC2, partners in the primary cilia in autosomal dominant polycystic kidney disease.
Yanda MK; Ciobanu C; Guggino WB; Cebotaru L
Am J Physiol Cell Physiol; 2023 Sep; 325(3):C682-C693. PubMed ID: 37519231
[TBL] [Abstract][Full Text] [Related]
16. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation.
Magenheimer BS; St John PL; Isom KS; Abrahamson DR; De Lisle RC; Wallace DP; Maser RL; Grantham JJ; Calvet JP
J Am Soc Nephrol; 2006 Dec; 17(12):3424-37. PubMed ID: 17108316
[TBL] [Abstract][Full Text] [Related]
17. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro.
Davidow CJ; Maser RL; Rome LA; Calvet JP; Grantham JJ
Kidney Int; 1996 Jul; 50(1):208-18. PubMed ID: 8807590
[TBL] [Abstract][Full Text] [Related]
18. Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
Arkhipov SN; Potter DL; Sultanova RF; Ilatovskaya DV; Harris PC; Pavlov TS
Physiol Rep; 2023 Apr; 11(7):e15652. PubMed ID: 37024297
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
20. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells.
Brill SR; Ross KE; Davidow CJ; Ye M; Grantham JJ; Caplan MJ
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10206-11. PubMed ID: 8816777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
